Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554061 | 1.00 | REN (0.64) | RENL3MBTL1MMEACECPA1 | |
| Hydrochloric Acid SCHEMBL6896628 | 0.99 | REN (0.62) | RENL3MBTL1MMEACECPA1 | |
| SCHEMBL29300391 | 0.95 | REN (0.59) | RENL3MBTL1MMEACECPA1 | |
| SCHEMBL27163859 | 0.92 | REN (0.60) | REN | |
| SCHEMBL3409209 | 0.92 | REN (0.60) | REN | |
| SCHEMBL987969 | 0.92 | REN (0.60) | REN | |
| SCHEMBL29300413 | 0.91 | DPP7 (0.58) | RENMMEACECPA1ACE2 | |
| SCHEMBL16994019 | 0.87 | DPP7 (0.58) | REN | |
| SCHEMBL987955 | 0.87 | DPP7 (0.58) | REN | |
| SCHEMBL14628581 | 0.86 | REN (0.51) | RENCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2024-12-19 | — | — | US | claimed |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | claimed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | claimed |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-08-05 | — | — | US | claimed |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2024-12-19 | — | — | US | disclosed |
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-08-05 | — | — | US | disclosed |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | SRX CARDIO, LLC | 2020-11-03 | — | — | US | disclosed |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944619-B2 | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOL1 | REN 1115/4885L3MBTL1 178/4885MME 263/4885 |
| US-10821106-B2 | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity | PCSK9, LDLR, APOB | REN 1304/4885L3MBTL1 462/4885MME 315/4885 |
| US-20210236481-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | REN 1304/4885L3MBTL1 462/4885MME 315/4885 |
| US-20180237381-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | REN 1304/4885L3MBTL1 462/4885MME 315/4885 |
| US-20240415830-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | REN 1304/4885L3MBTL1 462/4885MME 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.